Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

932 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.
Clingan P, Ladwa R, Brungs D, Harris DL, McGrath M, Arnold S, Coward J, Fourie S, Kurochkin A, Malan DR, Mant A, Sharma V, Shue H, Tazbirkova A, Berciano-Guerrero MA, Charoentum C, Dalle S, Dechaphunkul A, Dudnichenko O, Koralewski P, Lugowska I, Montaudié H, Muñoz-Couselo E, Sriuranpong V, Oliviero J, Desai J. Clingan P, et al. Among authors: desai j. J Immunother Cancer. 2023 Oct;11(10):e007637. doi: 10.1136/jitc-2023-007637. J Immunother Cancer. 2023. PMID: 37848259 Free PMC article.
A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling.
Thavaneswaran S, Sim HW, Grady J, Espinoza D, Huang ML, Lin F, McGrath M, Desai J, Charakidis M, Brown M, Kansara M, Simes J, Thomas D. Thavaneswaran S, et al. Among authors: desai j. Oncologist. 2024 Dec 25:oyae339. doi: 10.1093/oncolo/oyae339. Online ahead of print. Oncologist. 2024. PMID: 39720993 Free article.
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
Bendell J, LoRusso P, Overman M, Noonan AM, Kim DW, Strickler JH, Kim SW, Clarke S, George TJ, Grimison PS, Barve M, Amin M, Desai J, Wise-Draper T, Eck S, Jiang Y, Khan AA, Wu Y, Martin P, Cooper ZA, Elgeioushi N, Mueller N, Kumar R, Patel SP. Bendell J, et al. Among authors: desai j. Cancer Immunol Immunother. 2023 Jul;72(7):2443-2458. doi: 10.1007/s00262-023-03430-6. Epub 2023 Apr 5. Cancer Immunol Immunother. 2023. PMID: 37016126 Free PMC article. Clinical Trial.
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
Kim TW, Bedard PL, LoRusso P, Gordon MS, Bendell J, Oh DY, Ahn MJ, Garralda E, D'Angelo SP, Desai J, Hodi FS, Wainberg Z, Delord JP, Cassier PA, Cervantes A, Gil-Martin M, Wu B, Patil NS, Jin Y, Hoang T, Mendus D, Wen X, Meng R, Cho BC. Kim TW, et al. Among authors: desai j. JAMA Oncol. 2023 Nov 1;9(11):1574-1582. doi: 10.1001/jamaoncol.2023.3867. JAMA Oncol. 2023. PMID: 37768658 Free PMC article.
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
Sacher A, LoRusso P, Patel MR, Miller WH Jr, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J; GO42144 Investigator and Study Group. Sacher A, et al. Among authors: desai j. N Engl J Med. 2023 Aug 24;389(8):710-721. doi: 10.1056/NEJMoa2303810. N Engl J Med. 2023. PMID: 37611121 Free article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 38010044
Correction: International Alliance of Urolithiasis (IAU) consensus on miniaturized percutaneous nephrolithotomy.
Zeng GH, Zhong W, Mazzon G, Zhu W, Lahme S, Khadgi S, Desai J, Agrawal M, Schulsinger D, Gupta M, Montanari E, Martinez JML, Almousawi S, Malonzo VEF, Sriprasad S, Durutovic O, Arumuham V, Ferretti S, Kamal W, Xu KW, Cheng F, Gao XF, Cheng JW, Somani B, Duvdevani M, Git KA, Seitz C, Bernardo N, Ibrahim TAA, Aquino A, Yasui T, Fiori C, Knoll T, Papatsoris A, Gadzhiev N, Zhanbyrbekuly U, Angerri O, Ramos HL, Saltirov I, Moussa M, Giusti G, Vicentini F, Suarez EB, Pearle M, Preminger GM, Wu QH, Chai CA, Ghani K, Maroccolo M, Brehmer M, Osther PJ, Zawadzki M, Tursunkulov A, Kytaibekovich MN, Abuvohidov AA, Lara CAR, Noori Z, Zanetti SP, Shrestha S, de la Rosette J, Denstedt J, Ye ZQ, Sarica K, Choong S. Zeng GH, et al. Among authors: desai j. Mil Med Res. 2024 Dec 16;11(1):79. doi: 10.1186/s40779-024-00579-8. Mil Med Res. 2024. PMID: 39676164 Free PMC article. No abstract available.
The 5-factor modified frailty index as a prognostic factor following stereotactic radiosurgery for metastatic disease to the brain from non-small cell lung cancer: A multi-center cohort analysis.
Rajkumar S, Kite T, Desai J, Lucido T, Mathieu D, Tripathi M, Singh N, Kumar N, Mantziaris G, Pikis S, Sheehan JP, Wegner RE, Shepard MJ. Rajkumar S, et al. Among authors: desai j. J Clin Neurosci. 2024 Dec 13;132:110979. doi: 10.1016/j.jocn.2024.110979. Online ahead of print. J Clin Neurosci. 2024. PMID: 39673841
932 results